共 511 条
[1]
Aas T(1996)Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nature Medicine. 2 811-814
[2]
Børresen AL(2018)Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: Temporal phases of Li–Fraumeni syndrome Current Opinion in Oncology. 30 23-29
[3]
Geisler S(2004)Multicenter international study of oxaliplatin/5-fluorouracil/leukovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: Oxaliplatin, fluorouracil and leukovorin as adjuvant treatment for colon cancer New England Journal of Medicine 50 2243-2251
[4]
Smith-Sørensen B(2014)Breast-cancer risk in families with mutations in PALB2 New England Journal of Medicine. 371 497-506
[5]
Johnsen H(2016)Radiation therapy for breast cancer: Literature review Medical Dosimetry. 41 253-257
[6]
Varhaug JE(1998)Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β Science 280 596-599
[7]
Amadou A(2007)A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395-402
[8]
Waddington Achatz MI(2018)DNA and chromosome damage induced by bleomycin in mammalian cells: An update Mutation Research/reviews in Mutation Research. 775 51-62
[9]
Hainaut P(2003)Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: Are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Annals of Oncology. 14 406-413
[10]
Andre T(2015)Hypothesis: Obesity is associated with a lower mutation threshold in Colon Cancer Journal of Cancer. 6 825-1372